Lispro mix 75/25 + Glargine

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes

Conditions

Type 2 Diabetes

Trial Timeline

May 1, 2003 โ†’ Dec 1, 2004

About Lispro mix 75/25 + Glargine

Lispro mix 75/25 + Glargine is a approved stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT00551538. Target conditions include Type 2 Diabetes.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00551538ApprovedCompleted